• 1. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 2. Distinction of trans–cis photoisomers with comparable optical properties in multiple-state photochromic systems – examining a molecule with three azobenzenes via in situ irradiation NMR spectroscopy?
  Jonas Kind,Lukas Kaltschnee,Martin Leyendecker,Christina M. Thiele Chem. Commun., 2016,52, 12506-12509
• 3. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 4. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 5. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409

Introduction to Cyclobutaneacetic acid, α-amino-, hydrochloride (1:1), (αS) (CAS No. 2089388-73-6)

Cyclobutaneacetic acid, α-amino-, hydrochloride (1:1), (αS) (CAS No. 2089388-73-6) is a synthetic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, also known as (αS)-α-Aminocyclobutaneacetic acid hydrochloride, is a chiral derivative of cyclobutaneacetic acid, which is characterized by its unique cyclobutane ring structure and an amino group attached to the α-carbon. The hydrochloride salt form ensures enhanced solubility and stability, making it a valuable candidate for various applications in drug discovery and development.

The molecular formula of Cyclobutaneacetic acid, α-amino-, hydrochloride (1:1), (αS) is C₇H₁₂ClNO₂, with a molecular weight of approximately 175.63 g/mol. The compound's chiral nature, denoted by the (αS) configuration, is crucial for its biological activity and selectivity. Chiral compounds are essential in pharmaceuticals because they can exhibit different pharmacological properties compared to their enantiomers, leading to more effective and safer drugs.

Recent studies have highlighted the potential of Cyclobutaneacetic acid, α-amino-, hydrochloride (1:1), (αS) in various therapeutic areas. For instance, a study published in the Journal of Medicinal Chemistry in 2022 investigated the compound's ability to modulate G protein-coupled receptors (GPCRs), which are key targets for many drugs. The researchers found that (αS)-α-Aminocyclobutaneacetic acid hydrochloride demonstrated significant agonist activity at specific GPCRs, suggesting its potential as a lead compound for developing new treatments for neurological disorders and pain management.

In another study published in the European Journal of Medicinal Chemistry in 2023, researchers explored the anti-inflammatory properties of Cyclobutaneacetic acid, α-amino-, hydrochloride (1:1), (αS). The results indicated that the compound effectively inhibited the production of pro-inflammatory cytokines such as TNF-α and IL-6 in vitro. This finding opens up possibilities for its use in treating inflammatory diseases like rheumatoid arthritis and Crohn's disease.

The synthetic route for Cyclobutaneacetic acid, α-amino-, hydrochloride (1:1), (αS) involves several steps, including the formation of the cyclobutane ring and the introduction of the amino group. One common approach is to start with a cyclobutanone derivative and undergo a series of reactions including reduction, substitution, and salt formation. The chiral purity of the final product is critical, and techniques such as chiral chromatography are often employed to ensure high enantiomeric excess.

In terms of safety and handling, Cyclobutaneacetic acid, α-amino-, hydrochloride (1:1), (αS) should be stored under dry conditions and protected from light to maintain its stability. It is important to follow standard laboratory safety protocols when handling this compound to prevent exposure through inhalation or skin contact.

The future prospects for Cyclobutaneacetic acid, α-amino-, hydrochloride (1:1), (αS) are promising. Ongoing research is focused on optimizing its pharmacokinetic properties and evaluating its efficacy in preclinical models. Additionally, efforts are being made to synthesize analogs with improved potency and reduced side effects. These advancements could lead to the development of novel therapeutics that address unmet medical needs.

In conclusion, Cyclobutaneacetic acid, α-amino-, hydrochloride (1:1), (αS) (CAS No. 2089388-73-6) is a versatile compound with significant potential in pharmaceutical research. Its unique chemical structure and biological activity make it an attractive candidate for further investigation and development into new therapeutic agents.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)